February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.
Bardoxolone looks dead after yesterday’s adcom vote, but what about omaveloxolone?
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.